Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells
P D Greenberg, D E Kern, M A Cheever, P D Greenberg, D E Kern, M A Cheever
Abstract
The ability of noncytolytic Lyt-1+,2- T cells immune to FBL-3 leukemia to effect eradication of disseminated FBL-3 was studied. Adult thymectomized, irradiated, and T-depleted bone marrow-reconstituted (ATXBM) B6 hosts were cured of disseminated FBL-3 by treatment with 180 mg/kg cyclophosphamide (CY) and adoptively transferred Lyt-1+,2- T cells obtained from congenic B6/Thy-1.1 donors immune to FBL-3. Analysis of the T cell compartment of ATXBM hosts treated and rendered tumor-free by this therapy revealed that the only T cells present in the mice were donor-derived Lyt-1+,2- T cells. In vitro stimulation of these T cells with FBL-3 tumor cells, which express class I but no class II major histocompatibility complex antigens, induced lymphokine secretion, but did not result in the generation of cytotoxic T lymphocytes (CTL). Thus, in a setting in which mice lack Lyt-2+ T cells, and in which no CTL of either host or donor origin could be detected, immune Lyt-1+,2- T cells, in conjunction with CY, mediated eradication of a disseminated leukemia. The results suggest that delayed-type hypersensitivity responses induced by immune T cells represent a potentially useful effector mechanism for in vivo elimination of disseminated tumor cells.
References
- J Immunol. 1973 Jan;110(1):277-82
- Proc Natl Acad Sci U S A. 1975 May;72(5):1848-51
- J Immunol. 1976 Oct;117(4):1267-74
- Cell Immunol. 1977 Jun 15;31(2):364-9
- J Immunol. 1978 Jun;120(6):2027-32
- J Immunol. 1978 Dec;121(6):2220-7
- J Immunol. 1979 Mar;122(3):1162-5
- J Immunol. 1979 Oct;123(4):1772-7
- J Exp Med. 1980 Jan 1;151(1):69-80
- J Immunol. 1980 Feb;124(2):851-4
- J Immunol. 1980 Aug;125(2):711-4
- J Immunol. 1980 Oct;125(4):1487-93
- J Exp Med. 1980 Oct 1;152(4):823-41
- Cancer Res. 1980 Dec;40(12):4428-32
- J Immunol. 1981 Jun;126(6):2100-3
- J Immunol. 1981 Aug;127(2):805-10
- J Exp Med. 1981 May 1;153(5):1044-57
- J Exp Med. 1981 Sep 1;154(3):952-63
- J Immunol. 1982 May;128(5):2134-6
- J Exp Med. 1982 Apr 1;155(4):1063-74
- J Immunol. 1982 Aug;129(2):550-6
- J Exp Med. 1982 Sep 1;156(3):844-59
- Proc Natl Acad Sci U S A. 1982 Sep;79(17):5384-7
- J Exp Med. 1983 Mar 1;157(3):828-42
- J Exp Med. 1983 May 1;157(5):1448-60
- J Immunol. 1983 Jul;131(1):315-8
- J Immunol. 1983 Aug;131(2):788-93
- Int J Cancer. 1983 Oct 15;32(4):491-500
- J Exp Med. 1984 Jan 1;159(1):57-67
- J Immunol. 1984 Apr;132(4):1632-8
- J Immunol. 1984 Apr;132(4):2117-22
- J Immunol. 1984 May;132(5):2259-65
- J Exp Med. 1984 May 1;159(5):1295-311
- J Natl Cancer Inst. 1984 May;72(5):1161-5
- J Immunol. 1984 Dec;133(6):3401-7
Source: PubMed